Biosimilars Subject To Brand-Level Rebate Requirement In Medicaid – CMS
Executive Summary
CMS determines biosimilars are subject to the 23.1% minimum drug rebate applicable to brands as a condition of participation in Medicaid, in recent guidance.
You may also be interested in...
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.